Afternoon Session
Alzheimer’s disease affects more than 55 million people worldwide, with numbers expected to rise significantly in the coming decades - placing increasing urgency on the need for earlier and more accurate diagnosis.
This talk will explore the latest data on innovative blood-based biomarkers, including p-tau217 and p-tau181, and their emerging role in improving diagnostic accuracy in Alzheimer’s disease. It will also provide an overview of the NeuroToolKit (NTK), a collaboration between academic and industry partners designed to generate high-quality, reproducible, and comparable biomarker data.
Together, these advances highlight the growing potential of blood-based biomarkers to support earlier diagnosis and more informed clinical decision-making, with the aim of improving outcomes for patients, families, and healthcare systems.